Compare XPOF & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | NKTX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.6M | 198.2M |
| IPO Year | 2021 | 2020 |
| Metric | XPOF | NKTX |
|---|---|---|
| Price | $4.10 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $5.60 | ★ $10.83 |
| AVG Volume (30 Days) | 717.8K | ★ 832.0K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.24 | 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,092,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.57 | $1.70 |
| 52 Week High | $9.25 | $3.72 |
| Indicator | XPOF | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.85 | 21.41 |
| Support Level | $3.83 | N/A |
| Resistance Level | $6.15 | $2.45 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 2.23 | 10.67 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.